Advanced search
Publication Cover
Expert Review of Respiratory Medicine Volume 5, 2011 - Issue 2
Submit an article Journal homepage
224
Views
35
CrossRef citations to date
0
Altmetric
Perspective

Viral infection and pulmonary hypertension: is there an association?

Carlyne D Cool University of Colorado Denver, Department of Pathology, Aurora, CO, USA. [email protected]; University of Colorado Denver, Division of Pulmonary Sciences and Critical Care Medicine, Aurora, CO, USA; University of Colorado Denver, Department of Pathology, Aurora, CO, USA. [email protected]; University of Colorado Denver, Division of Pulmonary Sciences and Critical Care Medicine, Aurora, CO, USA
,
Norbert F Voelkel Victoria Johnson Center for Obstructive Lung Diseases and Pulmonary and Critical Care Medicine Division, Virginia Commonwealth University, 1101 East Marshall Street, Sanger Hall, Richmond, VA 23298-0565, USA; Victoria Johnson Center for Obstructive Lung Diseases and Pulmonary and Critical Care Medicine Division, Virginia Commonwealth University, 1101 East Marshall Street, Sanger Hall, Richmond, VA 23298-0565, USA
&
Todd Bull University of Colorado Denver, Division of Pulmonary Sciences and Critical Care Medicine, Aurora, CO, USA; University of Colorado Denver, Division of Pulmonary Sciences and Critical Care Medicine, Aurora, CO, USA
Pages 207-216 | Published online: 09 Jan 2014

References

  • Simonneau G, Robbins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol.54, S43–S54 (2009).
  • BMPR2 gene Aldred MA, Vijayakrishnan J, James V et al. rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum. Mutat.27, 212–213 (2006).
  • Nana-Sinkam P, Oyer RJ, Stearman RS et al. Prostacyclin synthase promoter regulation and familial pulmonary arterial hypertension. Chest128, 612S (2005).
  • Cogan JD, Pauciulo MW, Batchman AP et al. High frequency of BMPRT2 exonic deleteions/duplications in familial pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.174, 590–598 (2006).
  • Hatano S, Strasser T. Primary Pulmonary Hypertension: Report on a WHO Meeting. October 15–17, 1973. World Health Organization, Geneva, Switzerland (1975).
  • Simonneau G, Galiè N, Rubin LJ et al. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol.43, 5S–12S (2004).
  • Cool CD, Stewart JS, Werahera P et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am. J. Pathol.155, 411–419 (1999).
  • Sitbon O, Humbert M, Xavier J et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation111, 3105–3111 (2005).
  • Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation99, 1197–1208 (1999).
  • Yung D, Widlitz AC, Rosenzweig EB et al. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation110, 660–665. (2004).
  • Beghetti M, Galiè N. Eisenmenger syndrome. A clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J. Am. Coll. Cardiol.53, 733–740 (2009).
  • Sakao S, Tatsumi K, Voelkel NF. Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respir. Res.10, 95–103 (2009).
  • Tuder RM, Groves B, Badesch DB et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am. J. Pathol.144, 275–285 (1994).
  • Tuder RM, Chacon M, Alger L et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J. Pathol.195, 367–374 (2001).
  • Du L, Sullivan CC, Chu D et al. Signaling molecules in nonfamilial pulmonary hypertension. N. Engl. J. Med.348, 500–509 (2003).
  • Mason NA, Springall DR, Burke M et al. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension. J. Pathol.185, 313–318 (1998).
  • Xue C, Johns RA. Upregulation of nitric oxide synthase correlates temporally with onset of pulmonary vascular remodeling in the hypoxic rat. Hypertension28, 743–753 (1996).
  • Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med.328, 1732–1739 (1993).
  • Golpon HA, Geraci MW, Moore MD et al. HOX genes in human lung: altered expression in primary pulmonary hypertension and emphysema Am. J. Pathol.158, 955–966 (2001).
  • Dorfmuller P, Zarka V, Durand-Gasselin I et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.165, 534–539 (2002).
  • Cool CD, Groshong SD, Oakey J, Voelkel NF. Pulmonary hypertension: cellular and molecular mechanisms. Chest128, 565S–571S (2005).
  • Wright L, Tuder RM, Wang J et al. 5-lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am. J. Respir. Crit. Care Med.157, 219–229 (1998).
  • Tuder RM, Cool CD, Geraci MW et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med.159, 1925–1932 (1999).
  • Achcar R, Yoshiki D, Rai PR et al. Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension. Chest129, 696–705 (2006).
  • Ameshima S, Golpon H, Cool CD et al. Peroxisome proliferator-activated receptor γ (PPARγ) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ. Res.92, 1162–1169 (2003).
  • Rai PR, Cool CD, King JA et al. The cancer paradigm of severe pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.178, 558–564 (2008).
  • Lee SD, Shroyer KR, Markham NE et al. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J. Clin. Invest.101, 927–934 (1998).
  • Yeager ME, Halley GR, Golpon HA et al. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ. Res.88, e8–e11 (2001).
  • Richter A, Yeager ME, Zaiman A et al. Impaired transforming growth factor-β signaling in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.170, 1340–1348 (2004).
  • Masri FA, Xu W, Comhair SA et al. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol.293, L548–L554 (2007).
  • Taraseviciene-Stewart L, Kasahara Y, Alger L et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J.15, 427–438 (2001).
  • Taraseviciene-Stewart L, Scerbavicius R, Stewart JM et al. Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy. Peptides26, 1292–1300, (2005).
  • Chang Y, Cesarman MS, Pess F et al. Identification of herpesviruslike DNA sequences in AIDS-associated Kaposi’s sarcoma. Science266, 1865–1869 (1994).
  • Memar OM, Rady PL, Tyring SK. Human herpesvirus-8: detection of novel herpesvirus-like DNA sequences in Kaposi’s sarcoma and other lesions. J. Mol. Med.73, 603–609 (1995).
  • Whitby D, Howard MR, Tenant-Flowers M et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi’s sarcoma. Lancet346, 799–802 (1995).
  • Chang Y, Antman K. Kaposi’s Sarcoma. N. Engl. J. Med.342, 1027–1038 (2000).
  • Jenner RG, Boshoff C. The molecular pathology of Kaposi’s sarcoma-associated herpesvirus. Biochim. Biophys. Acta1602, 1–22 (2002).
  • Ensoli B, Sgadari C, Barillari G, Sirianni MC, Sturzl M, Monini P. Biology of Kaposi’s sarcoma. Eur. J. Cancer37, 1251–1269 (2001).
  • Jensen KK, Manfra DJ, Grisotto MG et al. The human herpes virus 8-encoded chemokine receptor is required for angioproliferation in a murine model of Kaposi’s sarcoma. J. Immunol.174, 3686–3694 (2005).
  • Bais C, Santomasso B, Coso O et al. G-protein-coupled receptor of Kaposi’s sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature391, 86 (1998).
  • Pati S, Cavrois M, Guo HG et al. Activation of NF-κB by the human herpesvirus 8 chemokinereceptor ORF74: evidence for a paracrine model of Kaposi’s sarcoma pathogenesis. J. Virol.7, 8660 (2001).
  • Polson AG, Wang D, DeRisi J, Ganem D. Modulation of host gene expression by the constitutively active G protein-coupled receptor of Kaposi’s sarcoma-associated herpesvirus. Cancer Res.62, 4525 (2002).
  • Schwarz M, Murphy PM. Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF-κB and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant. J. Immunol.167, 505 (2001).
  • Yang TY, Chen SC, Leach MW et al. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi’s sarcoma. J. Exp. Med.191, 445–454 (2000).
  • Montaner S, Sodhi A, Molinolo A et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi’s sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell3, 23–36 (2003).
  • Flore O, Rafii S, Ely S et al. Transformation of primary human endothelial cells by Kaposi’s sarcoma-associated herpesvirus. Nature394, 588–592 (1998).
  • Dupin N, Fisher C, Kellam P et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi’s sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma. Proc. Natl Acad. Sci. USA96, 4546–4551 (1999).
  • Cesarman E, Mesri EA, Gershengorn MC. Viral G protein-coupled receptor and Kaposi’s sarcoma: a model of paracrine neoplasia? J. Exp. Med.191, 417–422 (2000).
  • Grisotto MG, Garin A, Martin AP et al. The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells. J. Clin. Invest.116, 1264–1273 (2006).
  • Calore EE. Herpes simplex 2 pneumonia. Braz. J. Infect. Dis.6, 305–308 (2002).
  • Smith FB, Arias JH, Elmquist TH, Mazzara JT. Microvascular cytomegalovirus endothelialitis of the lung: a possible cause of secondary pulmonary hypertension. Chest114, 337–340 (1998).
  • Marecki JC, Cool CD, Parr JE et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-Nef-infected macaques. Am. J. Respir. Crit. Care Med.174, 437–445 (2006).
  • Graziani A, Galimi F, Medico E et al. The HIV-1 Nef protein interferes with phosphatidylinositol 3-kinase activation 1. J. Biol. Chem.271, 6590–6593 (1996).
  • Linnemann T, Zheng YH, Mandic R et al. Interaction between Nef and phosphatidylinositol-3-kinase leads to activation of p21-activated kinase and increased production of HIV. Virology294, 246–255 (2002).
  • He JC, Husain M, Sunamoto M et al. Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways. J. Clin. Invest.114, 643–651 (2004).
  • Krautkramer E, Giese SI, Gasteier JE et al. Human immunodeficiency virus type 1 Nef activates p21-activated kinase via recruitment into lipid rafts. J. Virol.78, 4085–4097 (2004).
  • Olivetta E, Percario Z, Fiorucci G et al. HIV-1 Nef induces the release of inflammatory factors from human monocyte/macrophages: involvement of Nef endocytotic signals and NF-κ B activation. J. Immunol.170, 1716–1727 (2003).
  • Pellicelli AM, Barbaro G, Palmieri F et al. Primary pulmonary hypertension in HIV patients: a systematic review. Angiology52, 31–41 (2001).
  • Hughes JD, Rubin LJ. Primary pulmonary hypertension an analysis of 28 cases and a review of the literature. Medicine65, 56–72 (1986).
  • Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection, Chest100, 1268–1271 (1991).
  • Kim KK, Factor SM. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum. Pathol.18, 293–296 (1987).
  • Kanmogne GD, Kennedy RC, Grammas P. Is HIV involved in the pathogenesis of non-infectious pulmonary complications in infected patients? Curr. HIV Res.4, 385–393 (2003).
  • Mette SA, Palevsky HI, Pietra GG et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am. Rev. Respir. Dis.145, 1196–1200 (1992).
  • Opravil M, Pechere M, Speich R et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV cohort study. Am. J. Respir. Crit. Care Med.155, 990–995 (1997).
  • Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N. Engl. J. Med.332, 228–232 (1995).
  • Kestler HW 3rd, Ringler DJ, Mori K et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell65, 651–662 (1991).
  • James CO, Huang MB, Khan M, Garcia-Barrio M, Powell MD, Bond VC. Extracellular Nef protein targets CD4R T cells for apoptosis by interacting with CXCR4 surface receptors. J. Virol.78, 3099–3109 (2004).
  • Huang MB, Jin LL, James CO, Khan M, Powell MD, Bond VC. Characterization of Nef–CXCR4 interactions important for apoptosis induction. J. Virol.78, 11084–11096 (2004).
  • Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HV-1 gp120 proteins. Biochem. Biophys. Res. Comm.333, 1107–1115 (2005).
  • Fagan KA, McMurtry IF, Rodman DM. Role of endothelin-1 in lung disease. Respir. Res.2, 90–101 (2001).
  • Filippatos GS, Gangopadhyay N, Lalude O et al. Regulation of apoptosis by vasoactive peptides. Am. J. Physiol. Lung Cell. Mol. Physiol.281, L749–L761 (2001).
  • Hofman FM, Wright AD, Dohadwala MM, Wong-Staal F, Walker SM. Exogenous Tat protein activates human endothelial cells. Blood82, 2774–2780 (1993).
  • Humbert M, Monti G, Brenot F et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am. J. Respir. Crit. Care Med.151, 1628–31 (1995).
  • Bull TM, Cool CD, Serls AE et al. Primary pulmonary hypertension, Castleman’s disease and human herpesvirus-8. Eur. Respir. J.22, 403–407 (2003).
  • Winter SS, Howard TA, Ritchey AK, Keller FG, Ware RE. Elevated levels of tumor necrosis factor-β, γ-interferon, and IL-6 mRNA in Castleman’s disease. Med. Pediatr. Oncol.26, 48–53 (1996).
  • Nishi J, Maruyama I. Increased expression of vascular endothelial growth factor (VEGF) in Castleman’s disease: proposed pathomechanism of vascular proliferation in the affected lymph node. Leuk. Lymphoma.38, 387–394 (2000).
  • Moore PS, Boshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science274, 1739 (1996).
  • Neipel F, Albrecht JC, Ensser A et al. Human herpesvirus 8 encodes a homolog of interleukin-6. J. Virol.71, 839 (1997).
  • Nicholas J, Ruvolo VR, Burns WH et al. Kaposi’s sarcoma associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat. Med.3, 287 (1997).
  • Burger R, Neipel F, Fleckenstein B et al. Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood91, 1858–1863 (1998).
  • Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem.271, 736 (1996).
  • Cool CD, Rai PR, Yeager ME et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N. Engl. J. Med.349, 1113–1122 (2003).
  • Henke-Gendo C, Mengel M, Hoeper MM, Alkharsah K, Schulz TF. Absence of Kaposi’s sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.172, 1581–1585 (2005).
  • Nicastri E. Human herpesvirus 8 and pulmonary hypertension. Emerg. Infect. Dis.11, 480–482 (2005).
  • Laney AS, De Marco T, Peters JS et al. Kaposi sarcoma-associated herpesvirus and primary and secondary pulmonary hypertension. Chest127, 762–767 (2005).
  • Montani D, Achouh L, Marcelin AG et al. Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman’s disease. Eur. Respir. J.26, 969–972 (2005).
  • Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS3, 35–40 (2008).
  • Bélec L, Mohamed AS, Authier FJ et al. Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman’s disease. Blood9, 3643–3653 (1999).
  • Lesprit P, Godeau B, Authier FJ et al. Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. Am. J. Respir. Crit. Care Med.157, 907–911 (1998).
  • Bull TM, Meadows CA, Coldren CD et al. Human herpesvirus-8 infection of pulmonary microvascular endothelial cells. Am. J. Respir. Cell Mol. Biol.39, 706–716 (2008).
  • Humbert M, Morrell NW, Archer SL et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol.43, 13S–24S (2004).
  • Voelkel NF, Cool C, Taraceviene-Stewart L et al. Janus face of vascular endothelial growth factor: the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension. Crit. Care Med.30, S251–S256 (2002).
  • Durrington HJ, Upton PD, Hoer S et al. Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor II. J. Biol. Chem.285, 37641–37649 (2010).
  • Dias Batista M, Ferreira S, Sauer MM et al. High human herpesvirus 8 (HHV-8) prevalence, clinical correlates and high incidence among recently HIV-1-infected subjects in Sao Paulo, Brazil. PloS ONE4(5), e5613 (2009).
  • Young RH, Mark GJ. Pulmonary vascular changes in scleroderma. Am. J. Med.64, 998–1004 (1978).
  • Kcomt W, Nahavandi AA, Myaing M, Alkhalil C, Stein D. Hepatitis C and the heart: to beat or not to beat. Int. J. Cardiol.96, 147–149 (2003).
  • Moorman J, Saad M, Kosseifi S, Krishnaswamy G. Hepatitis C virus and the lung: implications for therapy. Chest128, 2882–2892 (2005).
  • Feitelson MA, Duan LX. Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am. J. Pathol.150, 1141–1157 (1997).
  • Su Q, Schröder CH, Hofmann WJ, Otto G, Pichlmayr R, Bannasch P. Expression of hepatitis B virus X protein in HBV-infected human livers and hepatocellular carcinomas. Hepatology27, 1109–1120 (1998).
  • Kandemir O, Polat A, Kaya A. Inducible nitric oxide synthase expression in chronic viral hepatitis. J. Clin. Invest.101, 1343–1352 (1998).
  • Yoo YD, Ueda H, Park K et al. Regulation of transforming growth factor-β1 expression by the hepatitis B virus (HBV) X transactivator. J. Clin. Invest.97, 388–395 (1996).
  • Moon EJ, Jeon CH, Kim KR et al. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1α. FASEB J.18, 382–384 (2004).
  • Suzuki T. Primary pulmonary hypertension in association with human T-cell lymphotropic virus type I in a hemophiliac. Ann. Intern. Med.123, 394 (1995).
  • Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum. Pathol.28, 434–442 (1997).
  • Hachulla E, Gressin V, Guillevin L et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum.52, 3792–3800 (2005).
  • Mukerjee D, St George D, Coleiro B et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann. Rheum. Dis.62, 1088–1093 (2003).
  • Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J. Rheumatol.29, 282–287 (2002).
  • Asherson RA, Higenbottam TW, Dinh Xuan AT, Khamashta MA, Huges GR. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J. Rheumatol.17, 1292–1298 (1990).
  • Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum.42, 899–909 (1999).
  • Jais X, Launay D, Yaici A et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum.58, 521–531 (2008).
  • Taraseviciene-Stewart L, Scerbavicius DK, Burns N, Cool CD, Nicolls MR, Voelkel NF. The protective role of T-lymphocytes in pulmonary vascular remodeling. Chest128, S571–S572 (2005).
  • Tamosiuniene R, Long C, Ambler K et al. Immune reconstitution prevents autoimmune inflammation and right ventricular remodeling in immunodeficiency-associated pulmonary hypertension. Circulation120, S1135 (2009).
  • Hamamdzic D, Kasman LM, LeRoy EC. The role of infectious agents in the pathogenesis of systemic sclerosis. Curr. Opin. Rheumatol.14, 694–698 (2002)
  • Harel L, Straussberg R, Rudich H, Cohen AH, Amir J. Raynaud’s phenomenon as a manifestation of parvovirus B19 infection: case reports and review of parvovirus B19 infection: case reports and review of parvovirus B19 rheumatic and vasculitic syndromes. Clin. Infect. Dis.30, 500–503 (2000).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.